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1. Introduction
Down syndrome (DS) is the most common congenital disorder in children, affecting one in 800
live births. While the large number of contiguous genes from a trisomy of chromosome 21
(HSA21) is expected to broadly affect various organ systems during development, significant
advances in medicine have been made in this disorder such that those with DS live fairly long
life spans. Individuals with DS, however, uniformly demonstrate some degree of mental
retardation. Arguably, cognitive disabilities are the more devastating aspect of DS disorder.
Part of the cognitive dysfunction lies not only in the progressive neuronal degeneration/cell
death and impaired neurogenesis seen in this developmental and degenerative disorder, but
also in the reduction in dendrite formation and spine density, resulting in a disruption of
synaptic function. These neurological endophenotypes seen in DS may not be merely due to
genomic imbalance from triplication of HSA21 genes, but also to additive influences on
associated genes within a given network or pathway and modification of gene expressions
caused by epigenetic factors including DNA methylation.
Epigenetic factors regulate gene expression largely through DNA modification. Histones are
alkaline proteins that package and order DNA into structural nucleosomes. Acetylation and
deacetylation, as well as methylation, of histones can modify the density of chromatin and
thereby regulate gene transcription through chromatin remodeling. In a parallel manner,
biochemical modification of DNA can occur through DNA methylation. This process involves
the addition of a methyl group to the 5 position of the cytosine pyrimidine ring or the number
6 nitrogen of the adenine purine ring. DNA methylation at the 5 position of cytosine has the
specific effect of reducing gene expression by physically impeding the binding of transcrip‐
tional proteins to the gene itself, or by recruiting protein complexes including methyl-CpG-
binding domain proteins (MBDs), histone deacetylases (HDACs) and other chromatin
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remodeling proteins. Furthermore, environmental factors such as chemical toxins or oxidative
stress can accumulate over time and effect gene transcription. Collectively, these processes
modify DNA transcription and may affect many neurodevelopmental processes.
Recent advances in high throughput screening of both mRNA expression and DNA methyl‐
ation have provided a means to examine changes in gene activation and expression, and to
understand the integral relationship between gene clusters in effecting particular pathways.
The following review begins by exploring the potential contribution of both genetic and
epigenetic factors in regulation of various DS endophenotypes. More specifically, our prior
work has examined changes in DS neural progenitor mRNA expression and has led us to
identify several important pathways affected in this disorder, such as oxidative stress,
mitochondrial dysfunction and gliogenesis. Ongoing studies suggest that changes in DNA
methylation in DS may have an effect on oxidative phosphorylation, ubiquitin proteolysis and
insulin signaling. The confirmation of mRNA and DNA methylation changes and the clarifi‐
cation of these possible causal pathways may have implications for impaired synaptic function
and neurogenesis, which contribute to the cognitive impairment seen in DS. These ongoing
studies may further provide informative targets for early pharmaceutical interference to
ameliorate the symptoms of mental retardation (MR) in DS.
2. Genetic mechanisms underlying the DS phenotype
The triplication of genes on HSA21 causes a wide spectrum of neurological phenotypes in DS,
including mental retardation. DS individual displays not only delayed linguistic skills and a
relatively low IQ (Intelligent Quotient) but also behavioral issues such as attention-deficit
disorder (sometimes with hyperactivity) and autism [1-5]. The cognitive impairments extend
further after development, as individuals with DS are more prone to develop Alzheimer’s type
dementia [6]. In addition, individuals with DS are susceptible to epilepsy in the form of
infantile spasms and tonic clonic seizures with myoclonus at early ages [7-9]. These patholog‐
ical abnormalities in humans are, in part, replicated in DS animal models which show defects
in learning, social interactions, memory, and seizures [10-14].
Several genes on HSA21 are implicated in the abnormal neurodevelopment in DS [15]. They
can affect cellular function at every stage of neural development, such as proliferation and
differentiation of neuroprogenitor cells, neuronal survival and death, synapse formation,
maturation and plasticity, as well as myelination. Disruption of each of these pathways can
conceptually contribute to the MR seen in DS. Moreover, HSA21 genes have global effects on
other genes; a meta-analysis of heterogeneous DS data identified 324 genes with consistent
dosage effects, 77 on HSA21 and 247 on non-HSA21 [16]. Therefore, the over-expression of a
not so small group of genes on HSA21 may initiate cascades of other signaling pathways on
other chromosomes thorough an interactive network. The combinatorial effects from activa‐
tion of these processes may further contribute to the impairments seen during neurodevelop‐
ment in DS.
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2.1. Genetic mechanisms underlying oxidative stress in DS
Increased levels of oxidative stress and reactive oxygen species (ROS) have commonly been
associated with the DS brain. Free radicals are thought to disrupt the mitochondrial respiratory
system, induce apoptosis of neurons and stimulate gliosis, which can further promote neuronal
damage. This cyclical pathway may contribute to neuronal losses during neurogenesis as well
as neuronal degeneration in adulthood. Several HSA21 genes have been implicated in
generation of ROS including DYRK1A, DSCR1, SOD1, ETS2, S100B, APP and BACH1 [15, 17].
Additionally, more recent studies would suggest a synergistic role for various HSA21 genes
in induction of this pathological process. For example, over-expression of HSA21 genes APP
and S100B synergistically increase hydrogen peroxide levels and decrease membrane potential
in the mitochondria of human DS neuroprogenitor cells. The combination of a loss of mito‐
chondrial integrity and an increase of oxidative stress promotes apoptosis (changes in caspase
and respiratory chain protein expression) and gliosis (increase of GFAP). S100B induction can
occur through RAGE (Receptor for Advanced Glycation Endproducts) with consequent
activation of JNK/p38 and JAK/STAT signaling. These stress response pathways are known to
serve as downstream effectors potentially relevant to reactive gliosis, induction of S100B and
glial associated aquaporin 4 [18, 19]. Increased levels of S100B and APP further enhance this
cyclical cascade by promoting RAGE activation and inflammation with reactive gliosis. Lastly,
multiple HSA21 genes have demonstrated enhanced APP-dependent toxic effects on the
mitochondria whereas network prediction analyses have shown that four HSA21 proteins are
components of the JAK/STAT pathway. These studies imply that an additional 19 HSA21
(among 2004 in total) proteins interact with components in this pathway [20]. These findings
reiterate the large cascade of molecules that can be perturbed in a pathway following over-
expression of a single gene.
Although oxidative stress in DS patients is considered to be a primary contributor of neuro‐
degeneration such as Alzheimer’s Disease (AD) in adult patients, evidences from both human
and animal models suggest that these same processes could also affect neurodevelopment and
cognitive function at a much earlier age [19, 21-23]. Oxidative stress could therefore not only
alter neuronal numbers through degeneration and changes in synaptic plasticity through
impaired mitochondrial function, but also affect the generation of neurons during develop‐
ment. In this respect, ongoing effects from over-expression of HSA21 genes likely promote the
cognitive dysfunction in DS throughout the lifetime of an individual with this disorder.
2.2. Genetics mechanisms underlying neurogenesis in DS
The observation of reduced cortical volume and decreased neuronal numbers in DS patients
and animal models could in part be attributed to a reduction in the generation of neurons
[24-27]. Over-expression of several HSA21 genes has been implicated in neurogenesis by either
altering the rate or proliferation or by changing cell fate specification. By over-expressing
HSA21-associated OLIG2, we observed a phenotypic shift in the neural progenitor pool toward
glial progenitor phenotypes, accompanied by a corresponding decrease in the number of
neuronal progenitors. This change can partly be explained by OLIG2-dependent inhibition of
the expression and activity of KCNA3 outward rectifying potassium channels whose activa‐
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tion stimulates proliferation of neural progenitors [28]. With respect to proliferation, APP over-
expression can antagonistically compete with APPBP1, a protein required for the cell cycle
progression from G1 to S phase [29]. Similarly, increased S100B levels stimulate p53 nuclear
accumulation and inhibit proliferation [30]. DYRK1A has alternatively been shown to phos‐
phorylate p53, impair G1/S phase transition and inhibit proliferation [31]. Finally, many HSA21
genes regulate neurogenesis through their effects on NGF, hedgehog, WNT, Notch and insulin
signaling pathways [20]. Changes in expression of various HSA21 genes can also regulate
subpopulations of progenitors. For example, microarray profiling of DS human neuroproge‐
nitors implicated a defect in interneuron neurogenesis through increased expression of glial
progenitor genes such as OLIG1, OLIG2, OMG and COUP-TF1/NR2F1 and downregulation of
the interneuron related genes DLX1, DLX2 and DLX5 [32].
2.3. Genetics mechanisms underlying synaptic formation, maturation and plasticity in DS
A reduction in brain volume in DS has been attributed to impaired dendritic and synaptic
maturation. Dendritic branching and spine number are dramatically reduced in pyramidal
neurons in the hippocampus, visual cortex and motor cortex after 4 months postnatal age in
individuals with DS [33-35]. The decreased number of spines is usually accompanied by
aberrant spine morphology including enlarged or irregular spine heads, and sparse, small,
short stalks intermingled with unusually long spines [34, 36]. In addition, DS brains also show
changes in expression levels of various synaptic proteins such as decreased SEPT6, SYN1,
SNAP-25, SYP and increased SYNJ1 levels [37-41]. Similar morphological changes have been
observed in DS animal models and correlate on a molecular level with synaptic protein level
changes and functionally with synaptic plasticity defects, observed through LTP, LTD and
imbalance of excitatory-inhibitory neurotransmission [42-50]. Many genes on HSA21 (TINM1,
SYNJ1, ITSN1; KCNJ6, KCNJ15, KCNE1, KCNE2; NRIP1, ETS2, PCP4, DSCR1, DYRK1A, S100B,
APP, OLIG1, OLIG2) have been implicated in the synaptic pathology in DS, and the resulting
phenotype likely involves a complex interrelationship between these various genes and their
direct or indirect effect on various synaptic proteins [15, 48]. For instance, Dyrk1A over-
expression could impair synaptic vesicle endocytosis, reduce dendrite branching and spine
density of neurons; these phenotypes might be attributed to Dyrk1A induced hyperphos‐
phorylation of Tau and APP, or other synaptic proteins such as SYNJ1, resulting in impaired
hippocampal-dependent learning [51-53]. Moreover, the multiple genetic interactions can
additively promote the pathological DS synaptic endophenotype, as more severe defects were
observed in Ts65dn mice than in Ts1Cje mice, the former of which contain a larger number of
HSA21 associated genes [54].
3. Epigenetic mechanisms underlying the DS phenotype
DNA methylation refers to a process of DNA modification that involves the enzymatic transfer
of a methyl group from a methyl donor S-adenosylmethionine to carbon 5 of cytosine at 5’-
CpG-3’ sites. The enzymes carrying out this reaction are called DNA methyltransferases
(DNMTs). There are five members in this family: DNMT1, DNMT2, DNMT3A, DNMT3B and
Down Syndrome240
DNMT3L. DNMT1 is responsible for DNA methylation maintenance while DNMT3A and
DNMT3B are involved in de novo DNA methylation. DNMT2 is involved in RNA methylation.
DNMT3L (DNA methyltransferase 3-like) does not have enzymatic activity but can stimulate
DNMT3A and DNMT3B activation [55-57]. The addition of a methyl group to cytosine may
physically impede the binding of transcriptional factors to the gene itself, or by recruiting
protein complexes including methyl-CpG-binding protein 2 (MECP2), methyl-CpG-binding
domain proteins (MBDs), HDACs and other chromatin remodeling proteins [58]. Alternative‐
ly, other enzymes involved in DNA demethylation can reverse this process. These molecules
include cytidine deamination (AID, APOBEC) for deamination of cytosine and 5-methylcyto‐
sine and hydroxylation (TETs) for converting 5-methylcytosine to 5-hydroxymethylcytosine
[59]. DNA modification, especially in the promoter region, by these various regulators may
alter gene expression, and thereby affect many physiological processes [60]. In this context,
proteins that affect the methylation machinery in DS are likely to alter gene expression and
contribute to the DS phenotype.
Epigenetic modification is thought to be an important contributor to development and
numerous diseases. Several disorders associated with cognitive impairment such as X-linked
alpha-thalassemia mental retardation (ATRX) syndrome, Rett syndrome, and Rubinstein–
Taybi Syndrome involve some level of disruption in gene regulation through epigenetic effects
[61]. The pathology is medicated by different mechanisms including histone modification,
chromosome remodeling, small RNAs (siRNA, miRNA and other non-coding RNA) regula‐
tion and DNA methylation. More directly, DNMT3B mutations are associated with Immuno‐
deficiency, Centromere instability and Facial anomalies syndrome (ICF) with MR, suggesting
that epigenetic alterations in the expression of genes regulating neurogenesis, axon branching,
and neuronal migration such as IGF1 and ROBO1, contribute to cognitive impairment [62].
Certain features in DS may, in a similar fashion, be caused by epigenetic changes. For instance,
HSA21 genes DYRK1A, BRWD1 and RUNX1 are associated with SWI/SNF complex, a
chromatin remodeling complex that regulates the expression of subsets of genes such as
HDMTs, HMTs and HDACs- histone modification proteins involved in controlling the
expression of various interacting genes [63-65]. HSA21 genes CHAF1B and HMGN1 express
chromatin constitutive proteins involved in nucleosome assembly, which controls gene
expression through DNA methylation and histone methylation or acetylation [66, 67]. Over-
expression of HSA21 derived miRNA miR-155, miR802 in DS brain could also inhibit MECP2
expression, thereby mimicking MECP2 loss of function in Rett syndrome with mental retar‐
dation. MECP2 transcriptionally activates and silences CREB1 and MEF2C, genes that are
critical in neurodevelopment [68-70]. DNA methylation is another extensively studied
epigenetic regulator, being shown as impaired in many diseases. Although its importance has
been recognized in cancers, its involvement in neurological disorders such as DS has not been
well studied yet.
Several observations suggest that DNA methylation may play an important role in the DS
endophenotype. Oxidative stress from over-expression of various HSA21 genes [15] could
modulate DNA methylation directly through DNA damage or modification at the CpG sites,
thereby preventing normal binding of DNMTs to DNA [71, 72]. DNMT3L is localized on
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HSA21, and its triplication in DS suggests aberrant levels of expression. DNMT3L can form a
heterotetramer with DNMT3A, and increased DNMT3L levels could potentially promote
release of DNMT3A as well as increase its methylation activity [56]. DNMT3L can also
stimulate DNMT3B activity directly [57, 73]. In addition, Dnmt3a modulates neurogenesis and
synaptic plasticity in developing mouse neuroprogenitors and mature neurons by regulating
related genes expression, such as Bdnf, Reln, Dlx2, Gbx2, Sp8 and Stat1 [74-77]. It remains to be
seen whether other HSA21 genes in addition to DNMT3L can change the expression or activity
of various epigenetic modifiers including the DNMTs, MBDs, HDACs or TETs. Overall,
epigenetic modification provides an added layer of complexity to the interactive network
established from over-expression of genes on HSA21. These modifiers also server as attractive
candidates for targeting in DS given the broad effects they potentially have on a particular
phenotype.
Next, we will discuss how DNA methylation could be involved in some important neurode‐
velopmental phenotypes in DS.
3.1. Epigenetic mechanisms underlying oxidative stress in DS
While excessive oxidative stress leading to mitochondrial dysfunction is a main feature of DS
neurodevelopment, its effects on DNA methylation are not known. Currently no direct
evidence demonstrates a role for oxidative stress in regulating DNA methylation changes in
DS brain. However, DNA methylation studies from cancer seem to provide some clues. For
instance, hydroxyl radicals generated from hydrogen peroxide can cause DNA damage
including base modifications, deletions, and breakages, which could consequently interfere
with normal function of DNMTs, leading to global hypomethylation in cancer cells [78]. 8-
OHdG in CpG dinucleotides or the presence of O6-methylguanine could inhibit adjacent
cytosine methylation [79-82] by inhibiting DNMTs or MBDs binding [83]. By extension, some
of these same pathological mechanisms in cancer cells will likely be relevant in DS.
Methylation changes in the subset of DS genes involved in oxidative stress can contribute to
similar phenotypes seen in DS development and disease. For instance, Dnmt1 conditional
knockout in neural progenitor cells induced precocious astrogliogenesis through demethyla‐
tion of S100b, Gfap and Stat1 promoters and activation of the JAK-STAT pathway. Silencing of
these genes occurs through Mecp2 mediated inactivation of chromatin remodeling [84], with
demethylation resulting in an increase in S100B, GFAP and STAT1 expression. Enhanced
expression of these genes further promotes oxidative stress, cell death and gliosis. HSA21
localized APP could also be regulated by promoter dependent DNA methylation. The
methylation pattern in the APP promoter is different in different tissues and even in different
brain areas [85]. Hypomethylation of APP is found in the cerebral cortex of aging people and
AD patients [86, 87]; the methylation frequency of CpG sites on APP promoter in younger
people (26%) is higher than that in older people (8%), suggesting an age related methylation
difference [86]. Altered methylation patterns have also been implicated in deregulation of APP
processing enzymes PS1 and BACE in AD [88]. Finally, APP can also regulate the expression
of other genes such as CTIF, NTX2 and DDR2 through DNA methylation [89]. Overall, these
studies suggest that DNMTs appear to play some role in regulation of neurogenesis and
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neurodegeneration, and they do so by regulating several genes on HSA21 involved in oxidative
stress. Moreover, HSA21 genes associated with oxidative stress can influence the methylation
status of other genes.
3.2. Epigenetic mechanisms underlying neurogenesis in DS
DNA methylation regulates neurogenesis. Dnmts are broadly expressed in the brain and are
dynamically regulated [90, 91]. For example, Dnmt1 is expressed in both dividing neuropro‐
genitors and postmitotic neurons [91, 92]. Dnmt3b is mainly expressed in neuroprogenitor
cells during neurogenesis, whereas Dnmt3a is predominantly expressed in maturing brain
(including neural precursors, neurons, astrocytes and oligodendrocytes). Dnmt3a expression
peaks at three weeks after birth and then declines in adulthood [93, 94]. Dnmt3l directly
regulates Dnmt3a and Dnmt3b but is weakly expressed in the brain and does not appear to
disrupt normal cortical development. As for function, Hutnick et al used Emx1-cre to condi‐
tionally knockdown Dnmt1 exclusively in telencephalic precursors of mice, which induced
hypomethylation in excitatory neurons and astrocytes of cortex and hippocampus. The
methylation change increased neuronal apoptosis coupled with upregulation of apoptosis-
related genes such as Gadd45a, Casp4 and Ngfr. Loss of Dnmt1 also impaired neurogenesis,
maturation, learning and memory and was associated with downregulation of layer specific
gene such as Lhx2, neuronal channel genes such as Kcnh5, Kcnj9 and Scnn1a [95]. Interestingly,
Gadd45b could contribute to DNA demethylation of pro-neuronal genes such as BDNF and
FGF [96]. Studies using postnatal neural stem cells (NSC) in Dnmt3a knockout mice suggest
that Dnmt3a promotes non-promoter DNA methylation of neurogenesis genes such as Dlx2,
Gbx2 and Sp8 by functionally antagonizing Polycomb repression, resulting in increased
expression of these genes [77]. Finally, the expression pattern of Dnmt3b suggests that it may
be important for the early phase of neurogenesis (Feng et al., 2005).
DNA methylation may directly effect neural progenitor development in DS. In normal
development, Dnmt3l does not appear to have a significant phenotype in the developing
mouse cerebral cortex, likely due to its relatively low expression levels in the brain [97, 98],
(personal communications, Dr. Yi E. Sun, UCLA). DNMT3L, however, is located on chromo‐
some 21 and its triplication results in aberrantly high levels of expression in DS neuroproge‐
nitors (personal observations). Given that DNMT3L directly regulates both DNMT3A/B and
both these proteins have been implicated in neural progenitor development, a pathological
role for methylation genes such as DNMT3L in contributing to neurogenesis is likely.
3.3. Epigenetic mechanisms underlying synaptic formation, maturation and plasticity in DS
Several HSA21 genes can indirectly regulate epigenetic factors involved in synaptic function.
For example, SWI/SNF (SWItch/Sucrose NonFermentable) is a nucleosome-remodeling
complex that can destabilize histone-DNA interactions in an ATP-dependent manner. HSA21-
localized DYRK1A binds the SWI/SNF complex and subsequently induces a coordinated
deregulation of multiple genes that are responsible for dendritic growth [65]. Likewise, APP
has been shown to alter CpG methylation in three target genes CTIF (CBP80/CBP20-dependent
translation initiation factor), NXT2 (nuclear exporting factor 2), and hypermethylated DDR2
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[89]. DDR2 is a tyrosine kinase that functions as a cell surface receptor for fibrillar collagen and
regulates cell differentiation, remodeling of the extracellular matrix, cell migration, cell
proliferation, and cell cycle progression. More evidences from DNA methylation changing
synaptic function come from Dnmt transgenic mice. Dnmt1 and Dnmt3a knockout mice show
reduced LTP, deficits in learning and memory and deregulated genes expression associated
with synaptic plasticity [74]. Dnmt3a overexpression increases spine density in nucleus
accumbens [75]. DNMT3B is the gene mutated in ICF syndrome. Its mutation in lymphoblas‐
toid cell line from patients led to altered genes expression of several systems including
regulators of neurogenesis and synaptic function, such as ROBO1, JPH4, FRY, MAP4K4,
PCDHGC3, IGF1, SNCA, GABRA4 and BCHE [62]. Methyl-CpG binding protein 1 (MBD1), a
member of the methylated DNA-binding protein family, whose mutation leads to reduced
neurogenesis, decreased LTP and impaired spatial learning [99]. The involvement of Dnmts
and Hdacs in synaptic function is further supported by pharmacological manipulations
[100-102]. For instance, Dnmt inhibitors zebularine and 5-aza-2-deoxycytidine can alter DNA
methylation at promoters for Reln and Bdnf, and block the induction of LTP in synapses of
mouse hippocampus [103].
4. Global effects of DNA methylation in causing DS phenotypes
Several reports have shown global DNA methylation changes in DS [104, 105]. For example,
individual proteins on HSA21 such as beta amyloid (the protein encoded by HSA21 localized
APP) can induce global hypomethylation [106, 107]. Comparison of normal and DS methyla‐
tion in DS leukocytes and T lymphocytes using microarray-based profiling (MSNP (single
nucleotide polymorphism (SNP) chip-based method for profiling DNA methylation) identi‐
fied a small subset of genes with altered methylation, specific to the DS cell population [104].
Among the genes identified, five candidates (TMEM131, CD3Z, NOD2 and NPDC1) showed
correlation with RNA expression, and the methylation changes could be recapitulated by
exposing normal lymphocytes to the demethylation drug 5-aza-cytidine. These genes have
known or predicted roles in lymphocyte development. In order to gain some insights into the
DNA methylation deregulation in DS brain, we have performed some preliminary studies by
comparing the methylation profiles of control (CON) and DS frontal cortex from 18 gestational
weeks’ fetal brain using Illumina 450 Infinium Beadchip assay. Approximately 4% of the CpG
sites showed significant changes at the methylation level. When compared to CON baseline
methylated and unmethylated states, more CON unmethylated CpG sites became methylated
in DS than CON methylated states that became unmethylated. Moreover, there was overall
greater global hyper versus hypomethylation in DS compared to CON across all chromosomes,
except on HSA21. Chromosome 21 actually demonstrated a greater degree of hypo versus
hypermethylation in DS (unpublished data). Hypomethylation generally results in increased
gene transcription, whereas hypermethylation leads to the converse. Cross comparison of
DNA methylation states with the differential mRNA expression genes from previous micro‐
array studies, suggested epigenetic effects on several specific pathways (oxidative phosphor‐
ylation, insulin signaling and ubiquitination).
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4.1. Oxidative phosphorylation
Oxidative phosphorylation involves cellular metabolism through oxidation to produce ATP.
The broad methylation and gene expression changes in this pathway suggest its role as a
primary consequence of DS genes’ overdose effects. Plasma membrane NADPH oxidase is
considered a major producer of ROS in neurons or astrocytes in brain and is activated by S100B
through a RAGE-dependent pathway [108-111]. Over-expression of HSA21 genes such as
S100B and APP likely promote this pathway and cause cell death in DS neurons [19]. Small
amounts of superoxide anion and peroxide are also produced by the electron transport chain
in mitochondria [112-114]. The global deregulation of enzymes in this mitochondrial pathway
could thus disrupt the balance between oxidant generation and ATP production, result in
enhanced ROS generation and lead to diminished ATP levels [115, 116]. Several DS genes have
been implicated in this process. For instance, three HSA21 genes, ATP5J, ATP5O and NDUFV3
are components of ATP synthase and NADH dehydrogenase, though their expression and
regulation in DS brain are not known yet. In addition, other HSA21 genes may indirectly affect
this pathway. Alternatively, HSA21 gene S100B may target mitochondrial proteins such as p53
and ATPase ATAD3A, thereby assisting the cytoplasmic processing of proteins for proper
folding and subcellular localization [117-121]. Another HSA21 gene APP and its product beta
amyloid can interact with import receptors to gain entry into mitochondrial compartment,
where they accumulate and affect the normal function of this pathway [122, 123]. Finally, gene
expression in mitochondrial oxidative phosphorylation may be modulated by DNA methyl‐
ation. For instance, prenatal protein diet excess or restriction leads to hypomethylation of CpG
sites in the cytochrome C CYCS gene promoter, including those representing putative
transcription factor-binding sites. Elevation of this protein can alter electron transport chain
function in mitochondria and initiate apoptosis [124]. Our preliminary studies suggest there
is a broad change of DNA methylation and genes expression in this oxidative phosphorylation
pathway. Given the importance of ATP/ROS metabolism in mitochondrial function, further
studies will be needed to understand the epigenetic contribution to this pathway.
4.2. Insulin signaling
The insulin/insulin growth factor (IGF)-I pathway is a conserved pathway required for
neurogenesis and neuroprotection. It acts through IR/IGF-IR, IRS, and RAS/MAPK or
PI3K/AKT in regulating neurogenic cell fate [125]. Decreased levels of IGF-I have been found
to associate with growth retardation in DS patients, which could be rescued by GH therapy
[126, 127]. In addition, the insulin receptor knockout mouse suggests that neurons without
insulin receptor exhibit significant reduction of Akt and Gsk3beta and increased tau hyper‐
phosphorylation, characteristics of neurotoxicity in DS and AD [128]. Inhibition of the brain
insulin signaling pathways have been report in AD brain, with decreased expression of IR,
IRS1, IRS2, PI3K and AKT [129, 130]. This deficiency may, in part, involve DNA methylation
changes, given reports of co-localization of Hdac2 with insulin signaling components (Ir, Irs)
in postsynaptic glutamatergic neurons of the mouse hippocampus [131]. DNA methylation
changes in human DS progenitors (personal observations Lu and Sheen) also suggest that the
insulin-associated pathways may contribute to the DS endophenotype during development.
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4.3. Ubiquitin proteolysis
The ubiquitin proteasome/lysome system (UPLS) is responsible for the removal of excessive
proteins from multiple cellular compartments (especially mitochondria and synapses) in order
to maintain normal cellular function [132, 133]. Progression in DS cognitive impairment is
associated with accumulation of NF plaques and tangles, which have been shown to contain
ubiquitin [134]. Dystrophic neurites in DS also contain ubiquitin and the UPLS-associated
molecules PSMA5 and USP5 are upregulated in DS fetal brain [135]. Beta amyloid could
regulate synaptic protein degradation and function through ubiquitin pathway [136, 137].
Moreover, several E3 ubiquitin ligases have been shown to promote APP degradation [138,
139]. Additionally, HSA21 located genes AIRE and UBE2G2 are directly involved in the
ubiquitin pathway and could contribute to the phenotype. Taken in this context, disruption of
mitochondrial function (i.e. through S100B, APP, OLIG2 or disruption of the oxidative
phosphorylation pathway) might consequently impair ubiquitin-dependent lysosomal and
proteosomal clearance, because it is an ATP-dependent process. Finally, our preliminary
studies suggest that DNA methylation may also directly impair ubiquitin function. Loss of
ubiquitin function would have direct effects on synaptic function and structure (through beta
amyloid or synaptic proteins) but would also possibly enhance oxidative stress and mito‐
chondrial dysfunction. It is interesting to note that the high throughput DNA methylation
screen in DS invoked changes in methylation involving three networks (oxidative phosphor‐
ylation, insulin signaling, and ubiquitin function), which are highly dependent on one another.
5. Possible functions of DNMT3L in DS
Given that DNMT3A and DNMT3B are involved in neurogenesis and synaptic plasticity,
HSA21 localized DNMT3L regulates activities of DNMT3A/3B, suggesting that over-expres‐
sion of this gene will have pathological implications in methylation patterns involved in neural
development. Moreover, DNMT3L represses transcription by recruiting HDACs, which may
also affect the neurodevelopment [140, 141]. Dnmt3l null mice do not demonstrate a neuro‐
logical phenotype due to low levels of expression but rather exhibits defects in reproductive
organs where it is highly expressed and leads to imprinting and differentiation defect in early
stages of embryonic development [97, 98]. DNMT3L (R271Q) variant is associated with
significant DNA hypomethylation at the subtelomeric region in healthy human, though it does
not seem to cause any diseases [142]. On the other hand, over-expression of DNMT3L in Hela
cells mimics the characteristics of iPS cells and carcinogenesis by upregulating SOX2, HOX
genes and DNMTs including DNMT1 and DNMT3B expression, suggesting that DNMT3L
over-expression may change the DNA methylation profile in later stages of embryo develop‐
ment through activating DNMT3A/DNMT3B when neurogenesis and synapse formation
happen [143]. Interestingly, a recently developed DS model Dp(10)1Yey/+ mice harboring a
duplication spanning the entire HSA21 syntenic region on mouse chromosome 10 (Mmu10),
which contains Dnmt3l and S100b, did not show alterations in cognitive behaviors or hippo‐
campal LTP [144]. However, other mouse transgenic studies with over-expression of select
HSA21 genes (i.e. APP and S100b) have shown combinatorial effects in contributing to AD
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features in DS and neuronal survival [19, 145]. These observations would suggest combinato‐
rial and interactive effects between these genes in contributing to the MR seen in DS. It remains
to be seen whether DNMT3L effects on DNMT3A/B are responsible for the part of the
preliminary methylation defects seen in the several pathways discussed above. It is also not
known how the trisomy of HSA21 genes will effect methylation, but it is highly likely that
DNMT3L alters at least a subset of genes. In this respect, it will be important to identify the
causative methylation defects due to this single gene, as it will have implications for other DS
phenotypes.
6. Possible targets for pharmaceutical interference
The epigenetic screens in DS predict involvement of several mutually interactive pathways in
contributing to the neurological endophenotype in this disorder: oxidative phosphorylation,
insulin signaling, and ubiquitination. Approaches for therapeutic intervention possibly
involve either altering the methylation patterns or directly targeting specific pathways.
If global hypermethylation in DS neuroprogenitors is confirmed, then inhibition of DNMT or
DNA deamination could be used to rescue or treat the pathological phenotypes. There are two
clinical licensed DNMT inhibitors currently used in myelodysplastic syndrome, where they
relieve the repression of tumor suppressor genes: 5-aza-cytidine (Vidaza®) and 5-aza-2’-
deoxycytidine (Dacogen®) [59]. In addition, because of the occurrence of hypomethylation,
especially on HSA21, it would be desirable to develop a more specific methylation inhibitor/
activator or deamination activator/inhibitor in order to target specific promoters of genes in
important pathways.
Dysfunction of the UPLS system causes protein accumulation or over-degradation in cellular
organelles. Thus developing activator or inhibitor of proteasomes would have therapeutic
meaning. Most currently available activators/inhibitors of the ubiquitin-proteasome pathway
directly target the subunits of proteasome, the core of the proteolysis machinery, instead of
targeting upstream ubiquitination and recognition of ubiquitinated protein substrates by more
specific E3 ubiquitin ligases. Proteasome inhibitors such as Bortezomib, (Velcade®) are in
clinical treatment for multiple myeloma [146, 147]. Proteasome activators including 11s
activator, Blm10/PA200, and 19s activator are still under research.
Preservation of oxidative phosphorylation pathway and mitochondrial function can be
achieved through a new investigational drug EPI-743, currently in phase 2B/3 pivotal clinical
trials in Inherited Mitochondrial Respiratory Chain Disease [148]. EPI-743 is an orally absorb‐
able small molecule that readily crosses into the central nervous system. It works by targeting
an enzyme NADPH quinone oxidoreductase 1 (NQO1). Its mode of action is to synchronize
energy generation in mitochondria with the need to counter cellular redox stress [149].
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7. Conclusion
DS is a contiguous gene syndrome which gives rise to MR, dementia, and seizures. These
clinical outcomes are mirrored by endophenotypes including increased oxidative stress,
decreased neurogenesis and synaptic dysfunction. While these characteristics have largely
been attributed to HSA21 gene dosage effects, recent progresses in epigenetic studies have
raised the high likelihood that DNA methylation have significant effects on DS neurodevel‐
opment. Methylome screening suggests disruption of pathways involving oxidative phos‐
phorylation, ubiquitination and insulin signaling in DS. Candidate gene analyses suggest that
DNMT3L is over-expressed in DS given its location on chromosome 21. Alternatively, other
studies have implicated several HSA21 genes in altering methylation sites on genes involved
in these same pathways. The pathways invoked through epigenetic regulation contribute
directly to known pathological mechanisms identified on prior gene expression profiling such
as oxidative stress, gliosis, and mitochondrial dysfunction. In this respect, the DS brain
endophenotypes likely arise from the integration of various genetic and epigenetic factors on
chromosome 21.
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